ORBIMED ADVISORS LLC 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:01 pm Sale | 2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 71,889 2.900% | -86,356 (-54.57%) | Filing |
| 2022-02-11 4:12 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 158,245 7.900% | -42,376 (-21.12%) | Filing |
| 2021-02-12 4:39 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 200,621 10.250% | 86,000 (+75.03%) | Filing |